How many degraders are in the clinic, and where have they won approval?
Institution region
Approved degraders by year of first cancer approval
Class
Which degrader mechanisms have reached each stage in cancer?
Mechanism
ER degraders' Phase 3 hazard ratios
Progression-free survival in ESR1-mutant breast cancer; lower favors the degrader. Click a drug for its trial.
Which oncology PROTACs are in the clinic, who owns them, and how far have they got?
Stage
Sponsor
Target
Where do late-stage cancer degraders cluster?
Phase
Show
Where have degraders won, and how close are the other validated targets?
Group
Did degrader deals buy platforms or drugs, and where did the upfront cash go?
Show
Yearsto
Modality
When do degraders help patients whose tumors resist current drugs?
Outlook
Degraders stopped where a drug is already approved
Through 2027, which new target could get a first degrader approval?
Event type
Have degrader-antibody conjugates (DACs) worked in patients yet?
Payload degrades
In myeloma, what answers IMiD resistance: stronger CRBN glues or new E3 ligases?
Share of patients whose CRBN is altered. Click a stage for the basis.
Click a drug for its Phase 3 design.
Ligase
What do we expect next?
Explore the Data Behind the Report
The Excel behind this report (Clinical Degrader Programs, Oncology PROTAC Map, Deals, and DAC Programs) is free for Sleuth Intelligence Community members. Not a member yet? Join the community.